Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, f
By Tom Okafor, Clinical Trials Correspondent
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent resear
By Dr. Eleanor Vance, Regulatory Affairs Editor
For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological advances, patients remain tethe
By Dr. Eleanor Vance, Regulatory Affairs Editor
The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates viruses, bacteria, abnormal cells, an
By Dr. Eleanor Vance, Regulatory Affairs Editor
Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half of hospital admissions,
By Dr. Eleanor Vance, Regulatory Affairs Editor
Antimicrobial resistance is accelerating across health systems and undermining routine care. Surgical prophylaxis, oncology regimens and neonatal medicine all depend on reliable antibiotics, yet resis
By Priya Raghavan, Biotech & Markets Analyst
For patients living with blood cancer or a severe blood disorder, a stem cell transplant is often the turning point between decline and recovery. Yet for years in the UK, the calendar has been the ene
By Dr. Eleanor Vance, Regulatory Affairs Editor
Community pharmacy in the UK has entered a decisive phase. Policy, funding, and data infrastructure now point to a model where pharmacies act as clinical hubs for chronic disease management, preventio
By James Whitfield, Manufacturing & Supply Chain Writer
Human gene editing sits at a pivotal point in modern medicine. Its capacity to change DNA with precision has moved from conjecture to clinical practice, raising hopes for curative treatments while ign
By Dr. Eleanor Vance, Regulatory Affairs Editor
Artificial intelligence is moving from pilot projects to practical tools across the NHS. The policy direction is clear, with a shift to community-based care and a focus on prevention, personalisation
By Megan Liu, Digital Health Reporter
Gene therapy is moving from specialist promise to established practice in 2025. Approvals have broadened across indications, clinical data in Huntington's disease have shifted expectations for neurolo
By Dr. Eleanor Vance, Regulatory Affairs Editor
Oral morphine sulphate supplied as Oramorph remains a first-line strong opioid when moderate to severe pain does not respond to weaker agents. The immediate release formulation supports fast onset, sh
By James Whitfield, Manufacturing & Supply Chain Writer
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy